0001246360-14-003716.txt : 20140904 0001246360-14-003716.hdr.sgml : 20140904 20140904172110 ACCESSION NUMBER: 0001246360-14-003716 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140902 FILED AS OF DATE: 20140904 DATE AS OF CHANGE: 20140904 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quinn Anthony CENTRAL INDEX KEY: 0001532219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 141083880 MAIL ADDRESS: STREET 1: 128 SPRING STREET, SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 form.xml PRIMARY DOCUMENT X0306 4 2014-09-02 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532219 Quinn Anthony 33 HAYDEN AVE LEXINGTON MA 02421 false true false false EVP, CMO & Head of R&D Common Stock 2014-09-02 4 M false 10000 23 A 35595 D Common Stock 2014-09-02 4 S false 8600 69.88 D 26995 D Common Stock 2014-09-02 4 S false 400 70.5 D 26595 D Common Stock 2014-09-02 4 S false 700 71.96 D 25895 D Common Stock 2014-09-02 4 S false 300 72.88 D 25595 D Stock Option (Right to Buy) 23 2014-09-02 4 M false 10000 0 D 2021-12-20 Common Stock 10000 30000 D The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 26, 2013. The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $69.46 to $70.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $70.47 to $70.55. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $71.47 to $72.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $72.69 to $73.04. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Christopher J. Heberlig, Attorney-in-Fact 2014-09-04